In vitro Glyco Engineering (IVGE)
Glycosylation is a common type of post-translational modification that can significantly influence protein stability, biological activity, and pharmacokinetics of the final products. One way to manipulate glycosylation is through IVGE.
LakePharma is teaming up with Roche CustomBiotech to offer custom IVGE service designed to improve therapeutic protein production. With a two-step reaction of galactosylation followed by sialyation, glycoforms can be enriched with known kinetics and predictable outcomes.
- Glycosylation affects the pharmacokinetics and functions of therapeutic proteins and antibodies and impacts the safety and efficacy profiles.
- The production of therapeutic antibodies or proteins with consistent glycosylation profiles has been and remains a considerable challenge to the biopharmaceutical industry.
- in vitro glycoengineering (IVGE) technology can modify glycosylation in a controlled manner after proteins are produced and purified, and thus can isolate glycosylation management from cell culture manipulations.
Benefits of IVGE
- Improve the homogeneity of glycosylation patterns per batch
- Achieve lot-to-lot consistency
- May improve serum half-life
- Improve the efficacy of the drug in vivo
At LakePharma, we have examined the efficiency and practicality of using IVGE to control glycosylation and improve product quality at scale. Both proteins and antibodies have been tested in IVGE. We have concluded that IVGE has significant advantages over traditional processes (cell line modifications, and/ or process optimization) in terms of product quality, development time, and overall cost. LakePharma has incorporated IVGE in process development service offerings.
Click here to learn more about LakePharma IVGE services.
Download LakePharma's podium presentation at Antibody Engineering conference in San Diego in December 2019 by clicking here.